Christophe Weber says growth and innovation are the metrics for success in Takeda Pharmaceutical Co.’s $62 billion purchase of Shire PLC. The first order of business is bringing global shareholders around to Japan’s biggest-ever outbound takeover.
The Takeda CEO is facing a 21 percent drop in the stock price since the company disclosed its interest in March, while Shire is trading £9 ($12) below the offer price of roughly £49 a share. He’s also contending with some domestic shareholders who are averse to expansion as Weber looks to create a global pharmaceutical giant.
Unable to view this article?
This could be due to a conflict with your ad-blocking or security software.
Please add japantimes.co.jp and piano.io to your list of allowed sites.
If this does not resolve the issue or you are unable to add the domains to your allowlist, please see out this support page.
We humbly apologize for the inconvenience.